All patients had a history of recurrent infections, the frequency of infections varied among patients with a median of 6 times a year (range 4–8 times a year) before the G‐CSF therapy and twice a year (0–4) after the G‐CSF treatment was started. The gene discussed is CSF3; the disease is infection.